Home/Filings/4/0001493152-21-007814
4//SEC Filing

Yeh Yung-Ping 4

Accession 0001493152-21-007814

CIK 0001349929other

Filed

Mar 31, 8:00 PM ET

Accepted

Apr 1, 9:29 PM ET

Size

10.8 KB

Accession

0001493152-21-007814

Insider Transaction Report

Form 4
Period: 2021-03-30
Yeh Yung-Ping
DirectorChief Innovation Officer
Transactions
  • Other

    Stock option (right to buy)

    2021-03-30+51,82551,825 total
    Exercise: $1.56Exp: 2030-05-22Common stock (51,825 underlying)
  • Award

    Stock option (right to buy)

    2021-03-30+150,000150,000 total
    Exercise: $4.61Exp: 2031-03-30Common stock (150,000 underlying)
  • Other

    Common Stock, $0.0001 par value

    2021-03-30+1,328,6021,328,602 total
Footnotes (3)
  • [F1]Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received shares of the Issuer's common stock, $0.0001 par value (the "Common Stock") in exchange shares of StemoniX common stock, $0.0001 owned prior to the merger.
  • [F2]Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. Subject to continued employment, 51,825 options vest upon the achievement of certain milestones.
  • [F3]The option award was made in accordance with the terms of the Issuer's 2021 Equity Incentive Plan. Subject to continued employment, the option vests as to 25% of the shares on March 30, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on April 30, 2022.

Documents

1 file

Issuer

Vyant Bio, Inc.

CIK 0001349929

Entity typeother

Related Parties

1
  • filerCIK 0001850320

Filing Metadata

Form type
4
Filed
Mar 31, 8:00 PM ET
Accepted
Apr 1, 9:29 PM ET
Size
10.8 KB